Zygolide becomes first FDA-approved generic pergolide for horses

CURRENT FULL VERSION: Dechra’s Zygolide has entered the U.S. equine market as the first FDA-approved generic pergolide tablet for horses with pituitary pars intermedia dysfunction, better known as PPID or equine Cushing’s disease. The FDA approved the drug on December 19, 2025, and announced that decision on January 9, 2026, saying the product is bioequivalent to Prascend, the branded pergolide product that has defined this category since 2011. (fda.gov)

That matters because PPID is a long-haul disease, and treatment success often depends as much on practical administration and sustained adherence as it does on the prescription itself. The Horse’s sponsored Zyoglide materials position the product around daily usability, promoting peppermint flavoring, scored tablets, clinical results, and affordability. Other carousel placements were even thinner on substance, functioning mainly as brand-awareness ads; one used the line “Rediscover the partnership with Zygolide,” while adjacent ad slides offered little additional clinical information beyond the fact that this was a paid promotional campaign. While those slides are promotional rather than editorial, they still reflect the commercial strategy behind this launch: build recognition quickly and frame chronic pergolide therapy as easier to start, easier to dose, and potentially less expensive to continue. (thehorse.com)

The FDA-approved label provides the clearest clinical details. Zygolide is indicated for control of clinical signs associated with PPID in horses, with a recommended starting dose of 2 mcg/kg orally once daily and a maximum labeled dose of 4 mcg/kg daily. The tablets are half-scored, and dosing is intended to the nearest one-half tablet increment. In the effectiveness dataset summarized in the product insert, 47 of 113 horses, or 41.6%, required a dose increase at Day 90, and the Day 180 treatment success rate was 76.1%. Improvement was reported across clinical sign categories and endocrine measures. (dechra-us.com)

Safety and handling will be familiar territory for veterinarians already managing horses on pergolide, but the label still deserves attention. FDA says the product is prescription-only, should not be crushed because splitting or crushing can increase human exposure, and should not be handled by people with prior adverse reactions to ergot derivatives. The insert also advises that pregnant or lactating women should wear gloves when administering it. In the field study, decreased appetite or inappetence was the most commonly reported adverse event, affecting 32.8% of treated horses, with most cases occurring in the first month. (fda.gov)

Outside the label, early industry messaging has centered on access and cost. A veterinary practice announcement in Indiana described Zygolide as a more cost-effective option for horses requiring long-term PPID treatment, echoing the affordability theme in The Horse carousel. I’d treat that as directional rather than definitive, since broad market pricing data are still limited and promotional copy is not the same as an independent cost analysis. The additional ad placements in The Horse reinforce that Dechra is putting marketing weight behind awareness, but they do not add meaningful evidence on pricing or outcomes. Still, the launch of a first generic in a chronic equine endocrine category usually signals at least some pressure on pricing and prescribing conversations. (skillmanvet.com)

Why it matters: For equine practitioners, this is less about a new mechanism than a new market dynamic. A generic pergolide could help clinics and pet parents stay with evidence-based PPID management instead of delaying treatment, stretching tablets inconsistently, or turning to less standardized alternatives when budgets get tight. The practical details also matter at the exam-room level: dose titration remains individualized, appetite changes need monitoring, and human handling precautions should be part of every dispensing conversation. Because nearly half the horses in the effectiveness database needed a dose increase by Day 90, follow-up testing and reassessment remain central, even if the product is easier to administer. (dechra-us.com)

What to watch: The next signals to watch are distributor availability, how aggressively generic pricing reshapes use relative to Prascend, and whether equine clinicians report measurable gains in adherence or earlier treatment initiation. It will also be worth watching for more independent commentary from internists and equine practices as Zygolide moves from approval news into routine case management during 2026. The early ad footprint in The Horse suggests Dechra wants broad visibility from the outset, but the more useful story for clinicians will be what happens after the marketing push: actual pricing, prescribing patterns, and day-to-day owner compliance. (skillmanvet.com; thehorse.com)